Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Kee

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Cancer Research Communications|December 12, 2023
Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment TerminationKristen Simmons, Jane V Thomas, Kaysia Ludford, et al.
ESMO Open|September 3, 2021
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancersE E Dumbrava, S G Call, H J Huang, et al.
Journal for Immunotherapy of Cancer|August 25, 2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)Benny Johnson, Cara L Haymaker, Edwin R Parra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reactionF Janku, H J Huang, T Fujii, et al.
Oncotarget|May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget|September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Cancer Research Communications|November 16, 2022
Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancerVan K Morris, Michael J Overman, Michael Lam, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
Cancer Cell|August 29, 2025
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF<sup>V600E</sup> metastatic colorectal cancerVan K Morris, Christine M Parseghian, Vahid Bahrambeigi, et al.
JNCI Cancer Spectrum|May 11, 2024
Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volumeEnoch Chang, Franklin C L Wong, Beth A Chasen, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Cancer Research Communications|December 12, 2023
Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment TerminationKristen Simmons, Jane V Thomas, Kaysia Ludford, et al.
ESMO Open|September 3, 2021
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancersE E Dumbrava, S G Call, H J Huang, et al.
Journal for Immunotherapy of Cancer|August 25, 2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)Benny Johnson, Cara L Haymaker, Edwin R Parra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reactionF Janku, H J Huang, T Fujii, et al.
Oncotarget|May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget|September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Cancer Research Communications|November 16, 2022
Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancerVan K Morris, Michael J Overman, Michael Lam, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
Cancer Cell|August 29, 2025
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF<sup>V600E</sup> metastatic colorectal cancerVan K Morris, Christine M Parseghian, Vahid Bahrambeigi, et al.
JNCI Cancer Spectrum|May 11, 2024
Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volumeEnoch Chang, Franklin C L Wong, Beth A Chasen, et al.
Pageof 6